About “antibody-based targeted tumor therapy”: humanized antibodies are the most important class of drugs in targeted tumor therapy, and the antibody drugs that have been applied in clinical practice mainly include three major categories: 1. antibodies that target the signal receptors on the surface of tumor cells, such as cetuximab and panitumumab, can specifically bind to the EGFR receptors on the surface of tumor cells and achieve efficient and specific killing of tumors through antigen-induced ADCC and CDC effects. EGFR receptors and achieve efficient and specific killing of tumors through antigen-induced ADCC and CDC effects. In addition, since the target molecules of currently marketed antibody drugs are mostly key signaling molecule receptors that control tumor cell proliferation, differentiation and anti-apoptosis, the application of antibodies can also block malignant signaling and promote tumor cell apoptosis; Antibodies targeting tumor angiogenesis, such as bevacizumab ( anti-VEGF) recombinant human vascular endothelial inhibitor? 3. Immunomodulatory antibodies (immune checkpoint inhibitors), such as antibodies targeting the immune checkpoint molecules PD-1 and CTLA4, have made significant progress in the treatment of various solid tumors, and in a recent clinical trial published in the journal NJEM, anti In a recent clinical trial published in NJEM, the combination of PD-1/CTLA4 antibodies achieved an objective response rate of more than 50% in advanced melanoma, and some patients achieved long-term tumor-free survival.